Cidara Therapeutics (CDTX) Equity Average: 2017-2025
Historic Equity Average for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $461.8 million.
- Cidara Therapeutics' Equity Average rose 274.57% to $461.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $461.8 million, marking a year-over-year increase of 274.57%. This contributed to the annual value of $77.5 million for FY2024, which is 784.82% up from last year.
- As of Q3 2025, Cidara Therapeutics' Equity Average stood at $461.8 million, which was up 43.67% from $321.4 million recorded in Q2 2025.
- Over the past 5 years, Cidara Therapeutics' Equity Average peaked at $461.8 million during Q3 2025, and registered a low of -$13.0 million during Q1 2024.
- Over the past 3 years, Cidara Therapeutics' median Equity Average value was $56.6 million (recorded in 2024), while the average stood at $112.9 million.
- Over the last 5 years, Cidara Therapeutics' Equity Average had its largest YoY gain of 7,191.34% in 2024, and its largest YoY loss of 3,984.90% in 2024.
- Quarterly analysis of 5 years shows Cidara Therapeutics' Equity Average stood at $10.2 million in 2021, then tumbled by 181.73% to -$8.3 million in 2022, then increased by 15.47% to -$7.1 million in 2023, then spiked by 2,077.72% to $139.5 million in 2024, then spiked by 274.57% to $461.8 million in 2025.
- Its Equity Average was $461.8 million in Q3 2025, compared to $321.4 million in Q2 2025 and $152.5 million in Q1 2025.